Live feed09:10:00·1737dPRReleasevia QuantisnowAbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's DiseaseByQuantisnow·Wall Street's wire, on your screen.ABBV· AbbVie Inc.Health Care
